These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The prevalence of sacroiliitis in patients with acne vulgaris using isotretinoin. Baykal Selçuk L; Aksu Arıca D; Baykal Şahin H; Yaylı S; Bahadır S Cutan Ocul Toxicol; 2017 Jun; 36(2):176-179. PubMed ID: 27764978 [TBL] [Abstract][Full Text] [Related]
27. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero. Lowenstein EB; Lowenstein EJ Clin Dermatol; 2011; 29(6):652-61. PubMed ID: 22014987 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness Of Oral Omega 3 In Reducing Mucocutaneous Side Effects Of Oral Isotretinoin In Patients With Acne Vulgaris. Zainab Z; Malik NA; Obaid S; Malik S; Aftab K; Mumtaz M; Pervez A; Syed Z J Ayub Med Coll Abbottabad; 2021; 33(1):60-63. PubMed ID: 33774956 [TBL] [Abstract][Full Text] [Related]
29. Observational retrospective study evaluating the effects of oral isotretinoin in keloids and hypertrophic scars. Guadanhim LR; Gonçalves RG; Bagatin E Int J Dermatol; 2016 Nov; 55(11):1255-1258. PubMed ID: 27419807 [TBL] [Abstract][Full Text] [Related]
32. Acute acne flare following isotretinoin administration: potential protective role of low starting dose. Borghi A; Mantovani L; Minghetti S; Virgili A; Bettoli V Dermatology; 2009; 218(2):178-80. PubMed ID: 19060474 [No Abstract] [Full Text] [Related]
33. The role of isotretinoin in acne therapy: why not as first-line therapy? facts and controversies. Rigopoulos D; Larios G; Katsambas AD Clin Dermatol; 2010; 28(1):24-30. PubMed ID: 20082946 [TBL] [Abstract][Full Text] [Related]
34. Dermabrasion for acne scars during treatment with oral isotretinoin. Bagatin E; dos Santos Guadanhim LR; Yarak S; Kamamoto CS; de Almeida FA Dermatol Surg; 2010 Apr; 36(4):483-9. PubMed ID: 20180836 [TBL] [Abstract][Full Text] [Related]
35. ABSORICA (isotretinoin): a new form. Scheinfeld N Skinmed; 2013; 11(2):117-9. PubMed ID: 23745231 [No Abstract] [Full Text] [Related]
36. Isotretinoin dosing: past, present, and future trends. Hirsch RJ; Shalita AR Semin Cutan Med Surg; 2001 Sep; 20(3):162-5. PubMed ID: 11594671 [TBL] [Abstract][Full Text] [Related]
37. On isotretinoin dosing, adverse effects, and efficacy. Berk DR Australas J Dermatol; 2011 May; 52(2):147-8; author reply 148. PubMed ID: 21605103 [No Abstract] [Full Text] [Related]
38. Isotretinoin (roaccutane) usage--a South African consensus guideline. National Dermatology Working Group. S Afr Med J; 1997 Oct; 87(10 Pt 2):1410-3. PubMed ID: 11496385 [TBL] [Abstract][Full Text] [Related]
39. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Rademaker M Australas J Dermatol; 2013 Aug; 54(3):157-62. PubMed ID: 23013115 [TBL] [Abstract][Full Text] [Related]
40. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. Zaenglein AL; Shamban A; Webster G; Del Rosso J; Dover JS; Swinyer L; Stein L; Lin X; Draelos Z; Gold M; Thiboutot D J Drugs Dermatol; 2013 Jun; 12(6):619-25. PubMed ID: 23839176 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]